Loading...
FIEGE HEALTHCARE LOGISTICS GMBH — Exemestane Import Profile: Suppliers, Formulations & Sources
Loading...
Pharmaceutical Importer · #4 buyer for Exemestane · $558.2K import value · 19 shipments · GERMANY · DGFT Verified
FIEGE HEALTHCARE LOGISTICS GMBH is the #4 importer of Exemestane from India with $558.2K in import value and 19 verified shipments. FIEGE HEALTHCARE LOGISTICS GMBH holds a 4.2% market share in Exemestane imports based in GERMANY. The company sources from 1 verified supplier across 10 formulations shipped to 1 country. Overall, FIEGE HEALTHCARE LOGISTICS GMBH imports 2 pharmaceutical products worth $2.8M across 2 therapeutic categories.
Verified from 19 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| INTAS PHARMACEUTICALS LIMITED | $558.2K | 19 | 100.0% |
FIEGE HEALTHCARE LOGISTICS GMBH sources Exemestane from 1 verified Indian supplier based on 19 customs records. The primary supplier is INTAS PHARMACEUTICALS LIMITED accounting for 100.0% of imports.
Buyers ranked immediately above and below #4 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CARDINAL HEALTH | UNITED STATES | $800.0K | 16 | $50.0K |
| 3 | BROCACEF NL HUB | NETHERLANDS | $699.9K | 20 | $35.0K |
| 4 | FIEGE HEALTHCARE LOGISTICS GMBH ★ | GERMANY | $604.5K | 19 | $31.8K |
| 2 | AUROBINDO PHARMA USA., INC, | UNITED STATES | $450.0K | 9 | $50.0K |
| 5 | CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $450.0K | 9 | $50.0K |
FIEGE HEALTHCARE LOGISTICS GMBH ranks #4 among 196 Exemestane importers from India. Average shipment value of $31.8K compared to the market average of $26.2K. The closest competitors by value are CARDINAL HEALTH and BROCACEF NL HUB.
Destination countries from 19 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| GERMANY | $558.2K | 19 | 100.0% |
FIEGE HEALTHCARE LOGISTICS GMBH imports Exemestane to 1 country. The primary destination is GERMANY receiving 100.0% of shipments worth $558.2K.
| Formulation | Value | Shipments |
|---|---|---|
| PH.DRU. & MED.: EXEMESTAN SANDOZ 25MG TABLETS (EXEMESTANE TABLETS 25MG EACH TABLET CONT: EXEMESTANE 25MG) [3885X6X15T] PNOS | $116.6K | 3 |
| PHARMA DRUGS AND MEDI EXEMESTANE 25MG 3X10T G1 SANDOZ ITALY AS PER INV | $96.6K | 3 |
| PHARMA DRUGS AND MEDI EXEMESTAN 25MG EACH TABLET CONTAINS: EXEMESTANE 25MGNOS | $96.1K | 3 |
| PHAR.DRUGS AND MED.: EXEMESTAN 25MG EACHTABLET CONTAINS: EXEMESTANE...25MG Net Wt.- 143.940 Kg. | $50.0K | 1 |
| PHAR.DRUGS AND MED.: EXEMESTANE 25MG 3X10T G1SANDOZ-ITALY Each film coated tablet contains: Exemestane Ph.Eur#.# 25 mg | $50.0K | 1 |
| PHAR.DRUGS AND MED.: EXEMESTANO 25MG 3X10T G1SANDOZ-SPAIN Each film coated tablet contains: Exemestane Ph.Eur#.# 25 mg | $40.6K | 1 |
| PHAR.DRUGS AND MED.: EXEMESTAN 25 G1 10X10TSAN-HEX- NOR/SWE Each film coated tablet contains: Exemestane Ph.Eur#.# 25 m | $35.1K | 1 |
What FIEGE HEALTHCARE LOGISTICS GMBH and other importers must comply with to import Exemestane from India
Federal Institute for Drugs and Medical Devices (BfArM) / European Medicines Agency (EMA) (BfArM/EMA)
Marketing Authorisation Application (MAA) under EU Directive 2001/83/EC. Decentralized or Mutual Recognition Procedure for generics. Requires CTD Module 1–5 dossier.
Typical timeline: 12–18 months via Decentralized Procedure
EU GMP (EudraLex Vol. 4) compliance; GMP certificate issued by competent authority; WHO Prequalification accepted as supporting evidence
India exported $5.1M worth of Exemestane through 1,533 shipments from 87 suppliers to 57 countries, serving 196 buyers globally. FIEGE HEALTHCARE LOGISTICS GMBH imports $558.2K of this total, accounting for 4.2% of India's Exemestane exports with 19 shipments from GERMANY. This is verified from 19 customs shipment records covering 10 distinct formulations.
FIEGE HEALTHCARE LOGISTICS GMBH's average Exemestane order value is $29.4K per consignment, based on 19 shipments totaling $558.2K. FIEGE HEALTHCARE LOGISTICS GMBH is based in GERMANY and ranks #4 among all Exemestane importers from India by value. The company sources from 1 verified supplier in India.
FIEGE HEALTHCARE LOGISTICS GMBH sources Exemestane from 1 verified Indian supplier: INTAS PHARMACEUTICALS LIMITED ($558.2K, 100.0%). This is based on 19 customs records.
FIEGE HEALTHCARE LOGISTICS GMBH ranks #4 among 196 Exemestane importers from India with a 4.2% market share. The top 3 importers are CARDINAL HEALTH ($800.0K), BROCACEF NL HUB ($699.9K), FIEGE HEALTHCARE LOGISTICS GMBH ($604.5K). FIEGE HEALTHCARE LOGISTICS GMBH processed 19 shipments from GERMANY.
FIEGE HEALTHCARE LOGISTICS GMBH imports 2 products worth $2.8M. Beyond Exemestane, top products include Gliclazide. View the complete FIEGE HEALTHCARE LOGISTICS GMBH profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Exemestane — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access order-level details, pricing data, supplier connections, and competitive analysis for FIEGE HEALTHCARE LOGISTICS GMBH's Exemestane imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
FIEGE HEALTHCARE LOGISTICS GMBH
Full Company Profile →
2 products · $2.8M total trade · 2 categories
| PH.DRU. & MED.: EXEMESTAN 25MG TABLETS EACH TABLET CONTAINS: EXEMESTANE 25MG [1057X10X10T] | $33.7K | 1 |
| PHARMA DRUGS AND MEDI EXEMESTAN SANDOZ 25 EACH TABLET CONTAINS: EXEMESTANE 25MGNOS | $20.1K | 3 |
| PH.DRU. & MED.: TANEXEL (EXEMESTANE) 25M | $19.4K | 2 |
FIEGE HEALTHCARE LOGISTICS GMBH imports 10 distinct Exemestane formulations from India. The top formulation is PH.DRU. & MED.: EXEMESTAN SANDOZ 25MG TABLETS (EXEMESTANE TA with 3 shipments worth $116.6K.
Wholesale Distribution Authorisation (WDA) and Manufacturing/Import Authorisation (MIA) required for importer. Qualified Person (QP) must certify each batch.
EU labeling per Directive 2001/83/EC; German language patient leaflet (PIL) mandatory; serialization under EU Falsified Medicines Directive (FMD)
Note: EU FMD serialization and tamper-evident packaging mandatory since February 2019. Indian API/FDF manufacturers must hold EU GMP certificate.
Regulatory information is provided for general reference based on publicly available BfArM/EMA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with BfArM/EMA or qualified regulatory affairs professionals for case-specific guidance.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 57+ countries, 196+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Verified from customs records
Access shipment-level records, supplier contacts, and formulation details for FIEGE HEALTHCARE LOGISTICS GMBH.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Exemestane. For current order-level data, contact TransData Nexus.